Nalidin (Naloxone Hydrochloride, Tilidine Hydrochloride)

Nalidin combines naloxone and tilidine, acting on opioid pathways to address both overdose and pain management.

• Opioid overdose: rapidly reverses respiratory depression, sedation and other life‑threatening effects of opioid toxicity.
• Moderate to severe pain: provides analgesia after conversion of tilidine to nortilidine, useful in acute and chronic pain settings.
• Post‑operative pain: manages postoperative discomfort when opioid analgesia is required but rapid reversal may be needed.

• Naloxone hydrochloride competitively blocks μ‑opioid receptors, displacing opioid agonists and reversing their central effects. Tilidine hydrochloride is a pro‑drug that is metabolised in the liver to nortilidine, a μ‑opioid receptor agonist, producing analgesia. The combined formulation therefore offers immediate opioid antagonism together with a metabolically activated analgesic component. The antagonistic action of naloxone occurs within minutes, while tilidine’s analgesic effect develops as nortilidine reaches peak plasma concentrations within 30‑60 minutes.

Nalidin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Dizziness: transient light‑headedness or vertigo.
• Sweating: increased perspiration, especially during reversal of opioid effects.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Seizures: convulsive episodes, particularly in patients with predisposition.
• Severe hypotension or hypertension: abrupt changes in blood pressure requiring medical attention.
• Anaphylactic reaction: life‑threatening allergic response with rash, swelling, and respiratory compromise.

When prescribing Nalidin, consider the following precautions to ensure safe use.

• Assess opioid dependence: evaluate risk of precipitated withdrawal before administration.
• Monitor cardiovascular status: watch for hypertension, tachycardia or hypotension during reversal.
• Avoid use in known hypersensitivity: contraindicated in patients allergic to naloxone or tilidine.
• Use with caution in hepatic impairment: metabolism of tilidine may be altered, requiring close observation.
• Pregnancy and lactation: consult specialist before use as safety data are limited.
• Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Nalidin can interact with other medicines; key interactions are categorized by clinical significance.

Major Interactions (Avoid)

• Other opioid antagonists: additive antagonism may eliminate needed analgesia.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): risk of enhanced respiratory depression when opioid effect is abruptly reversed.

Moderate Interactions (Monitor Closely)

• Opioid agonists: may reduce analgesic efficacy; dose adjustments may be required.
• MAO inhibitors: can increase risk of hypertensive episodes with tilidine.
• Serotonergic agents: potential for serotonin syndrome when combined with tilidine.